Q為何選擇Juvéderm®療程?
A
Juvéderm®是全球No.1長效透明質酸品牌†，全球銷量更達1億支7，深受用家愛戴。產品系列於法國製造，更獲歐盟CE及美國FDA認證8,9，並於全球110個市場上市24，安全性備受充分肯定。
QJuvéderm®產品系列如何能達致自然豐盈的改善效果？
A
Juvéderm®長效透明質酸與肌膚組織融合度佳22，令提昇豐盈效果長效自然達2年6！採用國際專利技術 VYCROSS™ ，製成5種不同濃度和承托力的產品，體貼不同用家對於面部輪廓、淡紋及長效膚質改善的需求2-5。
Q甚麼是Juvéderm®美感療程?
A
Juvéderm®美感療程注重全面美感協調，不再只局部改善單一位置31，例如只填虎紋雖有一定程度改善，但可能因忽略全面協調而令整體觀感上顯得不自然。透過Juvéderm®美感療程就能從根本改善輪廓老化，達致提昇、飽滿、淡紋等持久自然效果2-5，展現緊緻年輕感。
QJuvéderm®美感療程後會否失去輪廓獨特性？
A
不少女生對面部輪廓未感滿意，卻又憂慮療程後會「撞樣」，失去五官及輪廓的獨特性。其實只要選擇合適療程產品及由專業醫生調整療程劑量，就能呈現獨特的自然輪廓。Juvéderm美感療程以獨有精準輪廓分析，了解您的真正需要，為用家定制貼合您的個人化療程。
QJuvéderm®療程效果可以維持多久?
A
Juvéderm®療程效果持久但非永久。Juvéderm® VOLITE™彈滑亮肌療程效果可維持長達9個月5，Juvéderm®美感療程效果可維持長達12-24個月6,20,26,29,30。
Q哪些人不適合接受Juvéderm®療程?？
A
孕婦、餵哺母乳的婦女、未滿18歲、容易產生疤痕增生的體質、曾有嚴重過敏反應的病史，均不建議接受療程。凡接受療程前，請諮詢您的醫生。
Q接受Juvéderm®療程後, 要注意什麼?
A
建議在12小時內，不要化妝；在24小時內，請避免劇烈運動及攝取酒精；在2週內，請避免長時間暴露在日光或紫外線下， 及長時間身處於過熱或過冷的環境32-39。若在過程中或之後，有異常的紅、腫、熱、痛，或是皮膚有刺熱的疼痛或變色，應該立即通知您的醫生。
規劃客製化保養針劑
†Allergan. Unpublished Data. REF-74203. Juvéderm®, the world’s leading brand of hyaluronic acid facial fillers. Feb 2019. References: 1. De Maio, M. Aesthetic Plast Surg. 2021 Apr;45(2):690-709; 2. De Maio M, et al. Plast Reconstr Surg. 2017 Aug;140(2):265e-276e; 3. De Maio M, et al. Plast Reconstr Surg. 2017 Oct;140(4):540e-550e; 4. De Maio M. et. al. Plast Reconstr Surg. 2017 Sep;140(3):393e-404e; 5. Ogilvie P et al. J Cosmetic Dermatol. 2019;00:1-6; 6. Callan P et al. Clin Cosmet Investig Dermatol. 2013;6:81-9; 7. Allergan. Data on File. REF-96563. FILLERS GLOBAL NUMBER OF SYRINGES. May 2022. 100 million Juvederm® syringes manufactured worldwide from 2004 to April 2022; 8. VOLUX™, VOLUMA®, VOLIFT®, VOLBELLA® 及 VOLITE™ 均獲得歐盟 CE 認證. European Commission, Juvéderm hyaluronic acid based medical devices. EC certificate number: 3824296CE02; 3824296CE05; 3824296CE06; 3824296CE08; 3824296CE09, Aug 2019; 9. VOLUX™, VOLUMA®, VOLIFT® 及 VOLBELLA® (approval as VOLUX™ XC, VOLUMA® XC, VOLLURE® XC and VOLBELLA® XC in US) 均獲得美國 FDA 認證. U.S. Food and Drug Administration, Department of Health & Human Services. Juvéderm VOLUX XC approval letter P110033/S065, July 2022; Juvéderm VOLUMA XC approval letter P110033/S047, Jun 2020; Juvéderm VOLLURE XC approval letter P110033/S020, Mar 2017; Juvéderm VOLBELLA XC approval letter P110033/S053, May 2021; 10. Papakonstantinou E., et al. Dermatoendocrinol. 2012 Jul 1;4(3):253–258; 11. Tan KS, Oh SR, Priel A, Korn BS, Kikkawa DO (2011). Surgical Anatomy of the Forehead, Eyelids, and Midface for the Aesthetic Surgeon. In Master Techniques in Blepharoplasty and Periorbital Rejuvenation. (pp.11-24). Springer; 12. Mariwalla K. (2011). Rejuvenation of the Upper Face. Medscape Education; 13. Shin JW et al. Int. J. Mol. Sci. 2019,20(9),2126; 14. Niforos F et al. Clin Cosmet Investig Dermatol. 2019;12:791–98; 15. Allergan. Data On File. REF-80724. Juvéderm® VOLITE laboratory testing – immunohistochemistry; 16. Goodman GJ et al. Plast Reconstr Surg. 2015;136(5 Suppl):139–48; 17. Allergan. Unpublished Data. INT-JUV-1950127. VYCROSS® – longest duration of hyaluronic acid facial filler in clinical trials. Jan 2020; 18. Jones D and Murphy DK. Dermatol Surg. 2013;39:1602–12. 19. Raspaldo H et al. J Cosmet Dermatol. 2010;9:11–15; 20. Dayan S et al. Aesthet Surg J. 2020 Jun 15;40(7):767-777; 21. Ogilvie P et al. Aesthet Surg J. 2020 Aug 14;40(9):NP499-NP510; 22. Lebreton P. 2004. WO2004092222A2. Cross-linking of low and high molecular weight polysaccharides preparation of injectable monophase hydrogels and polysaccharides and hydrogels thus obtained; 23. De Maio M. Aesthetic Plast Surg. 2004;28:295-300; 24. Allergan. Unpublished Data. REF-80819. Juvéderm® is available in over 110 territories worldwide. Feb 2019; 25. De Maio M, et al. Plast Reconstr Surg. 2017 Aug;140(2):265e-276e; 26. Ogilvie P et al. Aesthet Surg J. 2020 Aug 14;40(9):NP499-NP510; 27: Beer K., et al. Dermatol Surg. 2021. 47(1), 80–85; 28. Ogilvie P et al. Dermatol Surg. 2020 Mar;46(3):376-385; 29. Ecclestron D, Murphy DK. Clin Cosmet Investig Dermatol. 2012;5:167-72; 30. Niforos F et al. Dermatol Surg. 2017;43(10):1271–80; 31. De Maio et. al., Plast Reconstr Surg, 2015 & 2017; 32. Signorini M et al. Plast Reconstr Surg. 2016 Jun;137(6):961e-71e; 33. Urdiales-Galvez F et al. Aesthetic Plast Surg. 2018 Apr;42(2):498-510; 34. Urdiales-Galvez F et al. Aesthetic Plast Surg. 2017 Jun;41(3):667-677; 35. de Almeida AT et al. Surg Cosmet Dermatol 2017;9(3):204-13. 36. Philipp-Dormston WG et al. J Eur Acad Dermatol Venereol. 2017 Jul;31(7):1088-1095; 37. Funt D & Pavicic T. Plast Surg Nurs. 2015 Jan-Mar;35(1):13-32; 38. Shah NS et al. J Am Acad Dermatol. 2002 Aug;47(2):241-4; 39. Fitzgerald R et al. Facial Plast Surg. 2016 Oct;32(5):532-55.
Juvéderm®(Hyaluronic Acid Gel with Lidocaine) 產品系列包括VOLUX™ (HKMD-190341),
VOLUMA® (HKMD-100411), VOLIFT® (HKMD-130324), VOLBELLA®(HKMD-210451) 及VOLITE™ (HKMD-180040)。
請向醫生或醫學美容中心諮詢切合您獨特需要的專屬療程方案。療程效果因人而異。療程後如有任何不良反應，請即向醫生查詢。
